Immunotherapy with PD-1 blockade is a first-line treatment for patients with advanced
melanoma, but unfortunately most patients progress on this therapy. Recent evidence suggests
that radiation can enhance the immune response in the presence of checkpoint blockade. The
investigators aim to determine if radiation can elicit increased immune responses in patients
who have stable or progressive disease on nivolumab.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins